Solvay Settles Estratest False Marketing Suit For $16M

By Mike Cherney

Law360, New York (March 18, 2010, 3:38 PM ET) -- A federal judge has granted final approval to a $16.5 million class action settlement that will end a lawsuit accusing Solvay Pharmaceuticals Inc. of falsely marketing menopause-treating drugs as if they had been approved by the U.S. Food and Drug Administration.

Judge Richard Kyle of the U.S. District Court for the District of Minnesota signed off on the settlement Tuesday. Class members include people who purchased Solvay's Estratest or Estratest H.S. hormone replacement therapy drugs in the U.S., excluding California, since March 8, 1998.

As of...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles